» Articles » PMID: 16979848

First Injection of Ketamine Among Young Injection Drug Users (IDUs) in Three U.S. Cities

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2006 Sep 19
PMID 16979848
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Ketamine, a dissociative anesthetic, has emerged as an increasingly common drug among subgroups of young injection drug users (IDUs) in cities across the United States. In-depth qualitative interviews were conducted with 213 young IDUs aged 16-28 years recruited in New York, New Orleans, and Los Angeles between 2004 and 2006. While some initiated injection drug use with ketamine, the drug was more frequently injected by IDUs with extensive polydrug using histories. IDUs initiating with ketamine commonly self-injected via an intramuscular mode of administration. The injection group provided crucial knowledge and material resources that enabled the injection event to occur, including ketamine, syringes, and injection skills. Injection paraphernalia was commonly shared during the first injection of ketamine, particularly vials of pharmaceutically-packaged liquid ketamine. Injection events infrequently occurred in a rave or club and more typically in a private home, which challenges ketamine's designation as a 'club' drug. The first injection of ketamine was a noteworthy event since it introduced a novel drug or new mode of administration to be further explored by some, or exposed others to a drug to be avoided in the future. Risk reduction messages directed towards young IDUs should be expanded to include ketamine.

Citing Articles

Prevalence and Correlates of Providing and Receiving Assistance With the Transition to Injection Drug Use.

Gicquelais R, Werb D, Marks C, Ziegler C, Mehta S, Genberg B Epidemiol Rev. 2020; 42(1):4-18.

PMID: 33024995 PMC: 7947591. DOI: 10.1093/epirev/mxaa008.


The experience of initiating injection drug use and its social context: a qualitative systematic review and thematic synthesis.

Guise A, Horyniak D, Melo J, McNeil R, Werb D Addiction. 2017; 112(12):2098-2111.

PMID: 28734128 PMC: 5673537. DOI: 10.1111/add.13957.


Effects of Ketamine on Levels of Inflammatory Cytokines IL-6, IL-1β, and TNF-α in the Hippocampus of Mice Following Acute or Chronic Administration.

Li Y, Shen R, Wen G, Ding R, Du A, Zhou J Front Pharmacol. 2017; 8:139.

PMID: 28373844 PMC: 5357631. DOI: 10.3389/fphar.2017.00139.


Factors associated with being asked to initiate someone into injection drug use.

Bluthenthal R, Wenger L, Chu D, Lorvick J, Quinn B, Thing J Drug Alcohol Depend. 2015; 149:252-8.

PMID: 25735468 PMC: 5048683. DOI: 10.1016/j.drugalcdep.2015.02.011.


Perceived Drug Use Functions and Risk Reduction Practices Among High-Risk Nonmedical Users of Prescription Drugs.

Silva K, Kecojevic A, Lankenau S J Drug Issues. 2014; 43(4):483-496.

PMID: 25477621 PMC: 4251706. DOI: 10.1177/0022042613491099.


References
1.
Lankenau S, Clatts M, Goldsamt L, Welle D . Crack Cocaine Injection Practices and HIV Risk: Findings From New York and Bridgeport. J Drug Issues. 2007; 34(2):319-332. PMC: 2136406. DOI: 10.1177/002204260403400204. View

2.
Clatts M, Goldsamt L, Yi H . Club drug use among young men who have sex with men in NYC: a preliminary epidemiological profile. Subst Use Misuse. 2005; 40(9-10):1317-30. PMC: 2735842. DOI: 10.1081/JA-200066898. View

3.
Patterson T, Semple S, Zians J, Strathdee S . Methamphetamine-using HIV-positive men who have sex with men: correlates of polydrug use. J Urban Health. 2005; 82(1 Suppl 1):i120-6. PMC: 3456168. DOI: 10.1093/jurban/jti031. View

4.
Clatts M, Heimer R, Abdala N, Goldsamt L, Sotheran J, Anderson K . HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. J Acquir Immune Defic Syndr. 2000; 22(2):194-9. DOI: 10.1097/00126334-199910010-00013. View

5.
Dillon P, Copeland J, Jansen K . Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend. 2003; 69(1):23-8. DOI: 10.1016/s0376-8716(02)00243-0. View